Bailard Inc. Buys New Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Bailard Inc. purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 14,300 shares of the biotechnology company’s stock, valued at approximately $128,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. increased its stake in shares of Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 6,174 shares during the period. FMR LLC boosted its holdings in Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 3,919 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter worth about $108,000. Atria Wealth Solutions Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at about $135,000. Finally, US Bancorp DE lifted its holdings in shares of Aurinia Pharmaceuticals by 61.9% in the 4th quarter. US Bancorp DE now owns 19,366 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 7,406 shares during the period. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $1,564,744.00. Following the completion of the transaction, the chief executive officer now owns 1,953,892 shares in the company, valued at $15,631,136. The trade was a 9.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Matthew Maxwell Donley sold 65,902 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $527,216.00. Following the transaction, the chief operating officer now owns 739,456 shares in the company, valued at $5,915,648. This represents a 8.18 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 335,593 shares of company stock worth $2,684,744. Company insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Aurinia Pharmaceuticals Stock Performance

AUPH opened at $8.67 on Thursday. The stock has a market cap of $1.24 billion, a P/E ratio of -57.80 and a beta of 1.22. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The firm has a fifty day moving average price of $8.13 and a 200 day moving average price of $7.86. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.